Plain-English translation of NCT04772079 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it can help children with moderate to severe plaque psoriasis. The study will measure how well the medication works, how your body processes it, and whether it is safe. Researchers will follow children in two age groups—ages 4 to 12 and ages 12 to 17—over several years.
Currently, treatment options for children with severe psoriasis are limited. This medication works differently than existing treatments, and doctors want to know if it's a safe and effective choice for young patients.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to receive either the new medication or a placebo (a dummy pill with no active ingredient), and neither you nor the study team will know which one you're getting. You'll visit the clinic regularly so doctors can check your skin, measure your psoriasis improvement, and monitor for any side effects. The main study lasts about a year, and if you and the doctors think it's helping, you can continue in an extended follow-up phase for up to 5 more years.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Argentina